Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Non-steric-zipper models for pathogenic ╬▒-synuclein conformers.

Schuman B, Won A, Brand-Arzamendi K, Koprich JB, Wen XY, Howson PA, Brotchie JM, Yip CM.

APL Bioeng. 2018 May 1;2(2):026105. doi: 10.1063/1.5023460. eCollection 2018 Jun.

2.

Beneficial Effects of Trehalose on Striatal Dopaminergic Deficits in Rodent and Primate Models of Synucleinopathy in Parkinson's Disease.

Howson PA, Johnston TH, Ravenscroft P, Hill MP, Su J, Brotchie JM, Koprich JB.

J Pharmacol Exp Ther. 2019 Jun;369(3):364-374. doi: 10.1124/jpet.118.255695. Epub 2019 Mar 27.

PMID:
30918068
3.

Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia.

Brigham EF, Johnston TH, Brown C, Holt JDS, Fox SH, Hill MP, Howson PA, Brotchie JM, Nguyen JT.

J Pharmacol Exp Ther. 2018 Nov;367(2):373-381. doi: 10.1124/jpet.118.247650. Epub 2018 Aug 7.

PMID:
30087157
4.

DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.

Johnston TH, Versi E, Howson PA, Ravenscroft P, Fox SH, Hill MP, Reidenberg BE, Corey R, Brotchie JM.

Neuropharmacology. 2018 Mar 15;131:116-127. doi: 10.1016/j.neuropharm.2017.11.046. Epub 2017 Nov 29.

PMID:
29197517
5.

The link between mitochondrial complex I and brain-derived neurotrophic factor in SH-SY5Y cells--The potential of JNX1001 as a therapeutic agent.

Kim HK, Mendon├ža KM, Howson PA, Brotchie JM, Andreazza AC.

Eur J Pharmacol. 2015 Oct 5;764:379-84. doi: 10.1016/j.ejphar.2015.07.013. Epub 2015 Jul 8.

PMID:
26164791
6.

Smilagenin attenuates beta amyloid (25-35)-induced degeneration of neuronal cells via stimulating the gene expression of brain-derived neurotrophic factor.

Zhang R, Wang Z, Howson PA, Xia Z, Zhou S, Wu E, Xia Z, Hu Y.

Neuroscience. 2012 May 17;210:275-85. doi: 10.1016/j.neuroscience.2012.03.017. Epub 2012 Mar 13.

PMID:
22441042
7.

Metabotropic glutamate receptor mGlu2 is resistant to homologous agonist-induced desensitization but undergoes protein kinase C-mediated heterologous desensitization.

Lennon SM, Rivero G, Matharu A, Howson PA, Jane DE, Roberts PJ, Kelly E.

Eur J Pharmacol. 2010 Dec 15;649(1-3):29-37. doi: 10.1016/j.ejphar.2010.08.038. Epub 2010 Sep 15.

PMID:
20826132
8.

PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease.

Visanji NP, Orsi A, Johnston TH, Howson PA, Dixon K, Callizot N, Brotchie JM, Rees DD.

FASEB J. 2008 Jul;22(7):2488-97. doi: 10.1096/fj.07-095398. Epub 2008 Mar 25.

PMID:
18364399
9.

Phenylglycine derivatives as antagonists of group III metabotropic glutamate receptors expressed on neonatal rat primary afferent terminals.

Miller JC, Howson PA, Conway SJ, Williams RV, Clark BP, Jane DE.

Br J Pharmacol. 2003 Aug;139(8):1523-31.

10.
11.

Synthesis of phenylglycine derivatives as potent and selective antagonists of group III metabotropic glutamate receptors.

Conway SJ, Miller JC, Howson PA, Clark BP, Jane DE.

Bioorg Med Chem Lett. 2001 Mar 26;11(6):777-80.

PMID:
11277518
12.

(S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord.

Thomas NK, Wright RA, Howson PA, Kingston AE, Schoepp DD, Jane DE.

Neuropharmacology. 2001 Mar;40(3):311-8.

PMID:
11166323

Supplemental Content

Loading ...
Support Center